Creating a topical solution combining finasteride and stemoxydine to treat hair loss, and the discussion of whether 15mg of finasteride would be sufficient for 60ml solvent.
The conversation discusses whether KX-826 is better than fluridil for hair loss treatment. A user claims fluridil is ineffective even when using 4 vials a day.
The user is using RU58841 for hair regrowth on the temples and is considering adding minoxidil. They are questioning the potential for vellus hairs to develop into fuller hair and the possibility of reactivating dormant follicles.
A user has been on 1mg finasteride daily for 10 months, initially seeing great results, but started shedding heavily again at the 7-month mark. They are considering whether to continue with finasteride or switch to dutasteride.
The conversation is about making a solution of RU58841 using propanediol instead of propylene glycol due to skin irritation. The user seeks advice on whether this substitution is acceptable.
Dutasteride tablets are less effective than softgel capsules because they require a fat-based environment for proper absorption. Softgel capsules, like Avodart, are designed to maximize bioavailability, while powdered tablets may result in significantly lower DHT suppression.
The user switched from topical to oral finasteride and minoxidil for hair loss and experienced swelling and sensitivity in the left chest area. They are concerned about these symptoms but noticed improvement after skipping a dose.
Dr. Toyos is recruiting more participants for a larger trial on hair loss treatments. The discussion mentions Minoxidil, finasteride, and RU58841 as potential treatments.
A user experienced increased hair density loss after 4 months on dutasteride combined with finasteride. They are also using topical dutasteride with azelaic acid and alfatradiol but cannot tolerate antiandrogens like RU58841 due to headaches.
The conversation discusses using estradiol mesotherapy to replicate hormone replacement therapy results while minimizing systemic exposure. It also covers the use of Spironolactone cream, which reportedly has no systemic side effects, and the potential risks of using bicalutamide and Spironolactone in men.